SGHT - Sight Sciences Inc

https://www.sightsciences.com

Hold Momentum: Bearish

Recent News

What's Going On With Sight Sciences Stock Tuesday? - Sight Sciences ( NASDAQ:SGHT )

UnitedHealthcare's updated policy covers OMNI and other procedures for glaucoma treatment starting October 1. Coverage applies to 30 million lives across UnitedHealthcare's commercial and individual exchange plans. Get the strategy to turn September's volatility into 10x trades →

Bullish

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

GlobeNewswire • 6 days, 4 hours ago • score: 0.28

UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free ...

Bullish

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO - Sight Sciences ( NASDAQ:SGHT )

Benzinga • 1 week, 5 days ago • score: 0.29

MENLO PARK, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc.

Bullish

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

GlobeNewswire • 2 weeks, 5 days ago • score: 0.47

MENLO PARK, Calif., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc. ( Nasdaq: SGHT ) ( Sight Sciences or the Company ) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, ...

Bullish

Sight Sciences, Inc. ( SGHT ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.17

Sight Sciences (SGHT) delivered earnings and revenue surprises of +8.00% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease - Sight Sciences ( NASDAQ:SGHT )

Benzinga • 1 month, 2 weeks ago • score: 0.40

MENLO PARK, Calif., July 30, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc.

Bullish

GlobeNewswire • 1 month, 2 weeks ago • score: 0.38

Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$7.03

52W Low

$2.03

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.46

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.25

EV/Revenue (<3 favorable)

1.73

P/S (TTM) (<3 favorable)

2.53

P/B (<3 favorable)

2.76

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

20.66%

Institutions (25–75% balanced)

50.31%

Shares Outstanding

52,367,000

Float

28,818,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

76,303,000

Gross Profit (TTM)

65,150,000

EPS (TTM)

-0.96

Profit Margin (>10% good)

-0.64%

Operating Margin (TTM) (higher better)

-0.60%

ROE (TTM) (>15% strong)

-0.57%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.09

Momentum

Bearish momentum

Value

-0.1328

-0.1127

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025